Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lihua Tong

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Safety|March 28, 2025
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) databaseLihua Tong, Yanling Yuan, Wanming He, et al.
Frontiers in Oncology|April 14, 2025
Case Report: Esophageal cancer under comprehensive treatment strategy-application and clinical outcome analysis of combined immunotherapy, targeted therapy, and low-dose radiotherapyYanling Yuan, Xingxi Pan, Lihua Tong, et al.
Frontiers in Pharmacology|March 10, 2025
Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system databaseWanming He, Lihua Tong, Yanling Yuan, et al.
Ambio|October 30, 2013
Toward a sustainable utilization of land resources in China: problems, policies, and practicesWuyang Hong, Feixue Li, Manchun Li, et al.
Frontiers in Oncology|June 21, 2024
Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired <i>EGFR</i> 19Del/T790M/<i>cis</i>-C797S mutation resistanceWanming He, Lihua Tong, Wen Yang, et al.
Breast (Edinburgh, Scotland)|July 28, 2019
Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based studyXingxi Pan, Wen Yang, Yongfa Chen, et al.
Journal of Gynecologic Oncology|October 20, 2020
Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysisXingxi Pan, Wen Yang, Zhongyong Wen, et al.
Gene|November 23, 2016
MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1Yingshan Luo, Lihua Tong, Hui Meng, et al.
Frontiers in Oncology|September 5, 2025
Efficacy and safety of radiotherapy combined with immunotherapy and targeted therapy versus immunotherapy plus targeted therapy alone in unresectable hepatocellular carcinoma: a retrospective studyYanling Yuan, Yongsheng Chen, Chumin Huang, et al.
Molecular and Cellular Biochemistry|September 21, 2016
KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancerLihua Tong, Yingshan Luo, Ting Wei, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|March 28, 2025
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) databaseLihua Tong, Yanling Yuan, Wanming He, et al.
Frontiers in Oncology|April 14, 2025
Case Report: Esophageal cancer under comprehensive treatment strategy-application and clinical outcome analysis of combined immunotherapy, targeted therapy, and low-dose radiotherapyYanling Yuan, Xingxi Pan, Lihua Tong, et al.
Frontiers in Pharmacology|March 10, 2025
Adverse drug reactions to atezolizumab in combination with bevacizumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system databaseWanming He, Lihua Tong, Yanling Yuan, et al.
Ambio|October 30, 2013
Toward a sustainable utilization of land resources in China: problems, policies, and practicesWuyang Hong, Feixue Li, Manchun Li, et al.
Frontiers in Oncology|June 21, 2024
Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired <i>EGFR</i> 19Del/T790M/<i>cis</i>-C797S mutation resistanceWanming He, Lihua Tong, Wen Yang, et al.
Breast (Edinburgh, Scotland)|July 28, 2019
Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based studyXingxi Pan, Wen Yang, Yongfa Chen, et al.
Journal of Gynecologic Oncology|October 20, 2020
Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysisXingxi Pan, Wen Yang, Zhongyong Wen, et al.
Gene|November 23, 2016
MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1Yingshan Luo, Lihua Tong, Hui Meng, et al.
Frontiers in Oncology|September 5, 2025
Efficacy and safety of radiotherapy combined with immunotherapy and targeted therapy versus immunotherapy plus targeted therapy alone in unresectable hepatocellular carcinoma: a retrospective studyYanling Yuan, Yongsheng Chen, Chumin Huang, et al.
Molecular and Cellular Biochemistry|September 21, 2016
KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancerLihua Tong, Yingshan Luo, Ting Wei, et al.
Pageof 2